Evidence map›Paper›PMID 36463277›Full record

ArticleJournal of nanobiotechnology2022

Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection.

Jian Huo, Angke Zhang, Shuqi Wang, Hanghang Cheng, Daopeng Fan, Ran Huang, Yanan Wang, Bo Wan, Gaiping Zhang, Hua He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A Spleen-Targeted Tolerogenic mRNA-LNPs Vaccine for the Treatment of Experimental Asthma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jian Huo *College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Angke Zhang *College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Shuqi Wang *College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Hanghang ChengCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Daopeng FanCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Ran HuangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Yanan WangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Bo WanCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Gaiping ZhangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China.
Hua HeCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural University, Zhengzhou, 450046, China. hehua1123@126.com.
Henan Agricultural University · CN

Funding

National Natural Science Foundation of China 51903074the Key Technologies R&D Program of Henan Province 212102310252the National Natural Science Foundation of major projects 31941001the Young TopNotch Talents Foundation of Henan Agricultural University 30500737
6 · The paper itself

Abstract

backgroundThe prevalence of viral infectious diseases has become a serious threat to public safety, economic and social development. Vaccines have been served as the most effective platform to prevent virus transmission via the activation of host immune responses, while the low immunogenicity or safety, the high cost of production, storage, transport limit their effective clinical application. Therefore, there is a need to develop a promising strategy to improve the immunogenicity and safety of vaccines.

methodsWe developed a splenic-targeting biomimetic nanovaccine (NV) that can boost protective humoral and cellular immunity against african swine fever virus (ASFV) infection. The universal PLGA nanoparticles (CMR-PLGA/p54 NPs) coated with mannose and CpG (TLR9 agonist) co-modified red blood cell (RBC) membrane were prepared, which comprised a viral antigen (p54) and can be served as a versatile nanovaccine for elevating protective immunity.

resultsCMR-PLGA/p54 NVs could be effectively uptaken by BMDC and promoted BMDC maturation in vitro. After subcutaneous immunization, antigen could be effectively delivered to the splenic dendritic cells (DCs) due to the splenic homing ability of RBC and DC targeting capacity of mannose, which promoted antigen presentation and DCs maturation, and further elicited higher levels of cytokines secretion and specific IgG titers, CD4

conclusionsThis study demonstrates the high potential of CMR-PLGA NPs as vaccine delivery carriers to promote humoral and cellular immune responses, and it provides a promising strategy to develop safe and effective vaccines against viral infectious diseases.

Indexed as

African Swine Fever VirusVirus DiseasesAnimalsBiomimeticsCD8-Positive T-LymphocytesMannoseSwineMannoseASFVBiomimetic nanovaccineCpGRed blood cell membraneTargeting

Identifiers

PMID36463277
PMCPMC9719655
OpenAlexW4310778795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.